Balentine LLC Neurocrine Biosciences Inc Transaction History

Balentine LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $9,128 - $10,061	-70 Reduced 3.02%	2,246 $309,000
Q4 2023 Feb 09, 2024	BUY	$106.07 - $132.76 $9,440 - $11,815	89 Added 4.0%	2,316 $305,000
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $209,382 - $260,781	2,227 New	2,227 $250,000
Q3 2020 Nov 02, 2020	SELL	$96.16 - $135.15 $865 - $1,216	-9 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $765 - $1,173	9 New	9 $1,000
Q3 2019 Nov 15, 2019	SELL	$83.82 - $101.5 $1,257 - $1,522	-15 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $1,083 - $1,369	15 New	15 $1,000

641

95.3M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Balentine LLC, based on Form 13F filings with the SEC.

Stay updated on Balentine LLC with notifications on news.